FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064651105> ?p ?o ?g. }

• W2064651105 abstract "Introduction: Patients who receive neoadjuvant chemotherapy (NAC) for breast cancer typically do not receive further cytotoxic chemotherapy after surgery. We hypothesized that some patients would have micrometastatic disease in the bone marrow (disseminated tumor cells, DTCs) or peripheral blood (circulating tumor cells, CTCs) after NAC. This study documented rates and factors predicting DTCs and CTCs after NAC.Methods: We prospectively evaluated patients undergoing surgery for stage I-III breast cancer. All patients had blood and bone marrow samples taken after completing systemic NAC. CTCs (per 7.5ml blood) were detected using the CellSearchTM system (Veridex). CTCs were defined as nucleated cells lacking CD45 but expressing cytokeratins (CK) 8, 18, or 19. DTCs were assessed using anti-CK antibody cocktail (AE1/AE3, CAM5.2, MNF116, CK8 and 18) following cytospin. The presence of ≥1 CK positive cells and ≥1 epithelial cells meeting morphologic criteria for malignancy was considered a positive result for DTCs and CTCs, respectively. Clinicopathologic factors correlated with DTCs and CTCs and response after NAC included: Her2/neu, estrogen receptor (ER), progesterone receptor (PR) and COX2 status as well as tumor size and grade. Complete pathologic response (pCR) was defined as lack of any residual invasive disease in primary tumor and regional lymph nodes after NAC. Statistical analyses used chi-square and Fischer9s exact test.Results: Results were available for 53 patients who had bone marrow and blood collected after NAC. Median follow-up was 26 months. Mean age was 52 years. NAC included anthracyclines and taxanes +/- trastuzumab. Forty percent of patients had either DTCs or CTCs after NAC. Six patients had DTCs amongst 11 patients (55%) who received trastuzumab as compared to those who did not 6/33 (18%), P=0.019. DTCs and CTCs were found in 10/43 patients (23%) and 11/43 patients (27%), respectively. Factors predicting the presence of DTCs after NAC were Her2/neu positivity (P=0.001) and COX2 positivity determined in the primary tumor at diagnosis (P=0.04). No statistically significant correlations were found between CTCs after NAC and primary tumor characteristics. Thirty percent of patients with evidence of DTCs and 10% with CTCs had a pCR. Among the 7 patients with pCR after NAC, 2 (28%) had DTCs and 2 (28%) had CTCs. Factors predicting pCR following NAC were Her2/neu positivity (P=0.0003) and ER negativity (P=0.044). In our analysis, the best predictor of the presence of DTCs and the most likely reason for pCR following NAC was Her2/neu positivity.Conclusions: A significant number of patients have persistent DTCs and/or CTCs after NAC. Interestingly, HER2 positive patients were more likely to have pCR but were also more likely to show persistence of DTCs following NAC. Follow-up is needed to determine if these patients comprise groups at higher risk for recurrence, and therefore benefit from additional chemotherapy or targeted therapies. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3020." @default.
• W2064651105 created "2016-06-24" @default.
• W2064651105 creator A5003104262 @default.
• W2064651105 creator A5004443463 @default.
• W2064651105 creator A5026737814 @default.
• W2064651105 creator A5027464426 @default.
• W2064651105 creator A5032240997 @default.
• W2064651105 creator A5032987754 @default.
• W2064651105 creator A5042475462 @default.
• W2064651105 creator A5048183722 @default.
• W2064651105 creator A5056052231 @default.
• W2064651105 creator A5076426660 @default.
• W2064651105 creator A5084086867 @default.
• W2064651105 creator A5085458148 @default.
• W2064651105 creator A5085916302 @default.
• W2064651105 date "2009-12-15" @default.
• W2064651105 modified "2023-09-27" @default.
• W2064651105 title "Predictors of Persistent Micrometastatic Disease after Neoadjuvant Chemotherapy." @default.
• W2064651105 doi "https://doi.org/10.1158/0008-5472.sabcs-09-3020" @default.
• W2064651105 hasPublicationYear "2009" @default.
• W2064651105 type Work @default.
• W2064651105 sameAs 2064651105 @default.
• W2064651105 citedByCount "0" @default.
• W2064651105 crossrefType "proceedings-article" @default.
• W2064651105 hasAuthorship W2064651105A5003104262 @default.
• W2064651105 hasAuthorship W2064651105A5004443463 @default.
• W2064651105 hasAuthorship W2064651105A5026737814 @default.
• W2064651105 hasAuthorship W2064651105A5027464426 @default.
• W2064651105 hasAuthorship W2064651105A5032240997 @default.
• W2064651105 hasAuthorship W2064651105A5032987754 @default.
• W2064651105 hasAuthorship W2064651105A5042475462 @default.
• W2064651105 hasAuthorship W2064651105A5048183722 @default.
• W2064651105 hasAuthorship W2064651105A5056052231 @default.
• W2064651105 hasAuthorship W2064651105A5076426660 @default.
• W2064651105 hasAuthorship W2064651105A5084086867 @default.
• W2064651105 hasAuthorship W2064651105A5085458148 @default.
• W2064651105 hasAuthorship W2064651105A5085916302 @default.
• W2064651105 hasConcept C121608353 @default.
• W2064651105 hasConcept C126322002 @default.
• W2064651105 hasConcept C142724271 @default.
• W2064651105 hasConcept C143998085 @default.
• W2064651105 hasConcept C2776694085 @default.
• W2064651105 hasConcept C2779013556 @default.
• W2064651105 hasConcept C2779399171 @default.
• W2064651105 hasConcept C2779786085 @default.
• W2064651105 hasConcept C2779823535 @default.
• W2064651105 hasConcept C2780007613 @default.
• W2064651105 hasConcept C2780283643 @default.
• W2064651105 hasConcept C530470458 @default.
• W2064651105 hasConcept C61238886 @default.
• W2064651105 hasConcept C71924100 @default.
• W2064651105 hasConcept C84606932 @default.
• W2064651105 hasConceptScore W2064651105C121608353 @default.
• W2064651105 hasConceptScore W2064651105C126322002 @default.
• W2064651105 hasConceptScore W2064651105C142724271 @default.
• W2064651105 hasConceptScore W2064651105C143998085 @default.
• W2064651105 hasConceptScore W2064651105C2776694085 @default.
• W2064651105 hasConceptScore W2064651105C2779013556 @default.
• W2064651105 hasConceptScore W2064651105C2779399171 @default.
• W2064651105 hasConceptScore W2064651105C2779786085 @default.
• W2064651105 hasConceptScore W2064651105C2779823535 @default.
• W2064651105 hasConceptScore W2064651105C2780007613 @default.
• W2064651105 hasConceptScore W2064651105C2780283643 @default.
• W2064651105 hasConceptScore W2064651105C530470458 @default.
• W2064651105 hasConceptScore W2064651105C61238886 @default.
• W2064651105 hasConceptScore W2064651105C71924100 @default.
• W2064651105 hasConceptScore W2064651105C84606932 @default.
• W2064651105 hasLocation W20646511051 @default.
• W2064651105 hasOpenAccess W2064651105 @default.
• W2064651105 hasPrimaryLocation W20646511051 @default.
• W2064651105 hasRelatedWork W1877005387 @default.
• W2064651105 hasRelatedWork W1965111461 @default.
• W2064651105 hasRelatedWork W2008990967 @default.
• W2064651105 hasRelatedWork W2076760117 @default.
• W2064651105 hasRelatedWork W2081610478 @default.
• W2064651105 hasRelatedWork W2086311446 @default.
• W2064651105 hasRelatedWork W2154403560 @default.
• W2064651105 hasRelatedWork W2163275841 @default.
• W2064651105 hasRelatedWork W2286601009 @default.
• W2064651105 hasRelatedWork W2531922865 @default.
• W2064651105 hasRelatedWork W2565611594 @default.
• W2064651105 hasRelatedWork W2590438489 @default.
• W2064651105 hasRelatedWork W2741956904 @default.
• W2064651105 hasRelatedWork W2762315274 @default.
• W2064651105 hasRelatedWork W2891956256 @default.
• W2064651105 hasRelatedWork W2898001343 @default.
• W2064651105 hasRelatedWork W2913051982 @default.
• W2064651105 hasRelatedWork W2954886659 @default.
• W2064651105 hasRelatedWork W3023752670 @default.
• W2064651105 hasRelatedWork W3205370745 @default.
• W2064651105 isParatext "false" @default.
• W2064651105 isRetracted "false" @default.
• W2064651105 magId "2064651105" @default.
• W2064651105 workType "article" @default.